PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Institutional & Insider Ownership
49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Alpine Immune Sciences shares are held by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are held by insiders. Comparatively, 54.7% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Get PhaseBio Pharmaceuticals alerts:Profitability
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PhaseBio Pharmaceuticals | -12,572.13% | N/A | -174.38% |
| Alpine Immune Sciences | -169.82% | -47.34% | -23.12% |
Analyst Recommendations
This is a summary of recent ratings and price targets for PhaseBio Pharmaceuticals and Alpine Immune Sciences, as provided by MarketBeat.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PhaseBio Pharmaceuticals | 0 | 5 | 0 | 0 | 2.00 |
| Alpine Immune Sciences | 0 | 0 | 3 | 0 | 3.00 |
PhaseBio Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 4,636.84%. Alpine Immune Sciences has a consensus target price of $15.67, suggesting a potential upside of 157.68%. Given PhaseBio Pharmaceuticals' higher probable upside, equities analysts clearly believe PhaseBio Pharmaceuticals is more favorable than Alpine Immune Sciences.
Risk and Volatility
PhaseBio Pharmaceuticals has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
Valuation & Earnings
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PhaseBio Pharmaceuticals | $10.83 million | 0.44 | -$131.07 million | ($2.13) | -0.04 |
| Alpine Immune Sciences | $23.44 million | 7.89 | -$50.33 million | ($1.92) | -3.17 |
Alpine Immune Sciences has higher revenue and earnings than PhaseBio Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Alpine Immune Sciences beats PhaseBio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About PhaseBio Pharmaceuticals
(Get Rating)
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
About Alpine Immune Sciences
(Get Rating)
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.